Neuroscience Institute Research and Clinical Trials
Saint Luke’s Marion Bloch Neuroscience Institute features a strong clinical research program to ensure our patients have access to the most innovative and effective treatments.
Leader in stroke research
Since testing intravenous tPA, the clot-busting drug used to reverse strokes, in the early 1990s, the Saint Luke’s stroke team has been involved in every major stroke intervention research trial. Early participation in trials testing mechanical devices to retrieve clots, led to our extensive experience in clot retrieval and made us leaders in acute stroke treatment.
National Institute of Health StrokeNet
National Institute of Health StrokeNet is consists of 25 regional coordinating centers across the U.S., a national coordinating center at the University of Cincinnati, and a national data management center at the Medical University of South Carolina. The primary goal of this StrokeNet is to maximize efficiencies to develop, promote, and conduct high-quality, multi-site clinical trials focused on key interventions in stroke prevention, treatment, and recovery.
Saint Luke’s Hospital of Kansas City is a part of the Mid-America Regional Coordinating Center (MARCC) housed at Washington University School of Medicine. Four high-volume stroke centers participate in MARCC including Barnes-Jewish Hospital, St. Louis University Hospital, Saint Luke’s Hospital, and the Order of St. Francis Medical Center. Each of these medical centers is a tertiary care hub with large networks of referring hospitals, and have extensive experience participating in multi-center stroke trials. Drawing from both rural and urban settings, MARCC hospitals admit almost 5,000 stroke patients per year, from diverse geographic locales, racial backgrounds, and socioeconomic strata. Dr. Karin Olds is the Principal Investigator and Sophia Fike is the Research Coordinator for Saint Luke’s.
Current StrokeNet trials at Saint Luke’s include:
- The SATURN trial aims to determine whether continuation vs. discontinuation of statin drugs after spontaneous lobar intracerebral hemorrhage (ICH) is the best strategy; and whether the decision to continue/discontinue statins should be influenced by an individual's Apolipoprotein-E (APOE) genotype.
- Sleep SMART is a study to determine whether treatment of obstructive sleep apnea with positive airway pressure after acute ischemic stroke reduces recurrent stroke, myocardial infarction and all-cause mortality 6 months after event
To learn more about our clinical trials, call 816-932-1880.
Other Neuro Institute clinical trials
Stroke
ARPEGGIO SCP-CL-0003: A Randomized, Placebo-Controlled, Double-Blind, Multicenter Study of the Safety and Neuroprotective Capacity of Scp776 in Subjects Undergoing Endovascular Thrombectomy for Acute Ischemic Stroke.
OCEANIC-STROKE 20604: A multicenter, international, randomized, placebo controlled, double-blind, parallel group and event driven Phase 3 study of the oral FXIa inhibitor asundexian (BAY 2433334) for the prevention of ischemic stroke in male and female participants aged 18 years and older after an acute non-cardioembolic ischemic stroke or high-risk TIA.
Brain Cancer
MOAB Pro00113395: A multicenter trial to identify optimal atezolizumab biomarkers in the setting of recurrent gliobastoma.
NVX-108-GBM-P2: A Phase 2 Study of NanO2(TM) Combined With Radiation and Temozolomide in Patients With Newly Diagnosed GBM (RESTORE).
NRG-BN011: A Phase III Trial of Lomustine-Temozolomide Combination Therapy Versus Standard Temozolomide in Patients With Methylated MGMT Promoter Glioblastoma
Supportive Care
TTX-CINP-202: A Randomized, Double-Blind, Placebo Controlled, Multicenter, Efficacy and Safety Trial of Single Cycle Tetrodotoxin in the Treatment of Chemotherapy Induced Neuropathic Pain
Clinical trials at Saint Luke’s Hospital Midwest Ear Institute
Perimodiolar Implant CAM5776: A pre-market, open-label feasibility, prospective, single-arm multicenter feasibility investigation of hearing performance using the Cl632 in adults with low-frequency residual hearing.
To learn more about our clinical trials, call 816-932-3777.